F Cavalli
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
02.02.2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
02.02.2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
01.12.2000Identifying breast cancer patients at high risk for bone metastases
01.12.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22.
01.04.2000Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
01.04.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22
Crivellari D, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R D, Rudenstam C M, Thürlimann Beat, Price K N, Coates A S, Hürny C, Goldhirsch A
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.
01.06.1999Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
01.06.1999Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S F, Thürlimann Beat, Hürny C
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.
01.06.1999Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
01.06.1999European journal of cancer (Oxford, England : 1990) 1999; 35:913-20
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Thürlimann Beat, Schmitz S F, Castiglione-Gertsch M, Hürny C
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Pagani O, Price K, Fey M, Simoncini E, Thürlimann B, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C, Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Senn H. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European journal of cancer (Oxford, England : 1990) 1998; 34:632-40.
01.04.1998Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
01.04.1998European journal of cancer (Oxford, England : 1990) 1998; 34:632-40
Pagani O, Price K, Fey M, Simoncini E, Thürlimann Beat, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C M, Goldhirsch A, Gelber R D, Castiglione M, O'Neill A, Senn H J
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Goldhirsch A, Price K, Pagani O, Fey M, Simoncini E, Cavalli F, Coates A, Crivellari D, Forbes J, Collins J, Lindtner J, Rudenstam C, Thürlimann B, O'Neill A, Castiglione M, Gelber R, Senn H. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997; 8:751-6.
01.08.1997Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI
01.08.1997Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997; 8:751-6
Goldhirsch A, Price K, Pagani O, Fey M F, Simoncini E, Cavalli F, Coates A, Crivellari D, Forbes J, Collins J, Lindtner J, Rudenstam C M, Thürlimann Beat, O'Neill A, Castiglione M, Gelber R D, Senn H J
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Thürlimann B, Castiglione M, Hsu-Schmitz S, Cavalli F, Bonnefoi H, Fey M, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24.
01.06.1997Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
01.06.1997European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24
Thürlimann Beat, Castiglione M, Hsu-Schmitz S F, Cavalli F, Bonnefoi H, Fey M F, Morant R, Löhnert T, Goldhirsch A
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Thürlimann B, Fey M, Senn H, Cavalli F, Jungi W, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9.
01.07.1996First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
01.07.1996Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9
Thürlimann Beat, Fey M, Senn H J, Cavalli F, Jungi W F, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Borner M, Cavalli F, Thürlimann B, Jungi W, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071-7.
01.10.1994First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
01.10.1994J Clin Oncol 1994; 12:2071-7
Borner M, Cavalli F, Thürlimann Beat, Jungi W F, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J P